Yes, KYBELLA™ may be used in combination with other procedures to enhance the neck and jawline. KYBELLA™ may be used in some patients as an alternative to liposuction. As KYBELLA™ eliminates unwanted fat in the submental area, it may be combined with other neck rejuvenation procedures to produce a more pleasing jawline and neck. For example, Forma (non-invasive radiofrequency) may provide additional skin tightening and lifting to complement the contouring effect from KYBELLA™. Skin resurfacing treatment options such as Fractora may be used to further improve fine lines and wrinkles of the face, neck, and jawline. A Photofacial or Lumecca IPL may be used to improve sun damage or brown spots of the face, jawline and neck to complement the fat reduction properties of KYBELLA™ by evening out skin tone.
KYBELLA™ injection, also known as ATX-101, is the first and only FDA-approved injectable drug that contours and improves the appearance of submental fullness due to submental fat. Treatments will reduce a double chin and contour the jawline with minimal downtime.
KYBELLA™ is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. KYBELLA™ causes the destruction of fat cells when injected in their general area. Once destroyed, those cells cannot store or accumulate fat contents. After the aesthetic response is achieved, retreatment with KYBELLA™ is not expected.
To avoid potential tissue damage, KYBELLA™ should not be injected into or in close proximity (1-1.5 cm) to the marginal mandibular nerve, salivary glands, lymph nodes and muscles.
The safety profile of KYBELLA™ is well-characterized. KYBELLA™ has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which over 1,600 have been treated with KYBELLA™. KYBELLA™ is manufactured through a highly-controlled, FDA-regulated process and approved facility to ensure patient safety.
The most common adverse reactions were edema/swelling, hematoma/bruising, pain, numbness, erythema and induration. Marginal mandibular nerve (MMN) injury occurred in 4% and dysphagia occurred in 2% of subjects. To avoid potential tissue damage, KYBELLA™ should not be injected into or in close proximity (1-1.5 cm) to the MMN, salivary glands, lymph nodes and muscles.
KYBELLA™ is administered by injections into the fat under the chin. Each in-office treatment session is typically 15-20 minutes. Treatment with KYBELLA™ is customized by the physician to the patient’s aesthetic goals for an improved chin profile.
Individual results may vary, but on average patients can see results after 2-3 treatments sessions.
Downtime is minimal with swelling, redness and tenderness at injection site. Varying degrees of swelling among patients occur. Bruising and numbness can also occur. Marginal mandibular nerve (MMN) injury occurred in 4% and dysphagia occurred in 2% of subjects. To avoid potential tissue damage, KYBELLA™ should not be injected into or in close proximity (1-1.5 cm) to the MMN, salivary glands, lymph nodes and muscles.
Soignez-Vous is the premier New York City MedSpa for aesthetic and beauty treatments. Refine your look and find your best you with a consultation with our highly-trained aesthetic experts today.
9 E 68th Street, 1C, New York, NY 10065